annb0t
Top 20
Bionomics Limited (NASDAQ: BNOX) announced results from its Phase PREVAIL study of BNC210 for the acute treatment of Social Anxiety Disorder (SAD). The trial enrolled 151 adult patients. The primary endpoint, measured by the change from baseline to the average of the Subjective Units of Distress Scale (SUDS) scores during a 5-minute Public Speaking Challenge, was not met in the BNC210-treated patients when compared to placebo. SUDS is a tool for quantifying the intensity of anxiety, fear, or dis...
>>> Read more: Bionomics' Social Anxiety Disorder Study Fails To Meet Primary Endpoint
>>> Read more: Bionomics' Social Anxiety Disorder Study Fails To Meet Primary Endpoint
